Finding studies
Finding studies
Take this into the appointment.
Saves the questions and what to expect into your notes, next to the visit they belong to.
Huji Xu, Ph.D, MD
CONTACT
Lead
Shanghai Changzheng Hospital
This is an investigator-initiated trial to evaluate the safety and efficacy of anti-CD19-CD3E-CAR-T cells in the relapse or refractory autoimmune diseases. Study intervention consists of a single infusion of CAR-transduced autologous T cells administered intravenously after a lymphodepleting therapy regimen consisting of fludarabine and cyclophosphamide. Interim analysis will be performed when participants finish the visit of 12 weeks after CAR-T cells infusion.
Age
18–65
Sex
ALL
Healthy volunteers
Not accepted